Moderna and BioNTech shares jumped 10.5 per cent and 6.1 per cent, respectively, on Tuesday as the vaccine makers benefited from news of the J&J pause.
Norway’s health authorities estimated that their vaccination plans could be delayed by eight to 12 weeks if they could not use either the J&J or the Oxford/AstraZeneca vaccine.
The biggest short-term loser here is Europe, not the United States. Nor will this help Australia reopen. But does the American median voter or median FDA senior bureaucrat care? What will the CVS liability lawyers advise from here on out? What will the French anti-vaxxers think?
Here is the full FT article.